(Q38726962)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

review article

1 reference

title

Pharmacotherapy for Fragile X Syndrome: Progress to Date (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Matthew H Davenport

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Tori L Schaefer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Katherine J Friedmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Craig A Erickson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

1 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

431-445

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26858239%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40265-016-0542-y

7 March 2020

exact match

0 references

cites work

The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Absence of expression of the FMR-1 gene in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

RNA-mediated neurodegeneration in fragile X-associated tremor/ataxia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Executive dysfunction in young FMR1 premutation carriers: forme fruste of FXTAS or new phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Premature ovarian failure among fragile X premutation carriers: parent-of-origin effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Primary ovarian insufficiency: a more accurate term for premature ovarian failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Co-occurring diagnoses among FMR1 premutation allele carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Advances in the treatment of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

What can we learn about autism from studying fragile X syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Fragile X spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Clinical and molecular implications of mosaicism in FMR1 full mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Methylation mosaicism of 5'-(CGG)(n)-3' repeats in fragile X, premutation and normal individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Molecular mechanisms of fragile X syndrome: a twenty-year perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

From FMRP function to potential therapies for fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Trajectories of early brain volume development in fragile X syndrome and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

The trouble with spines in fragile X syndrome: density, maturity and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Adult fragile X syndrome. Clinico-neuropathologic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Analysis of neocortex in three males with the fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Altered synaptic plasticity in a mouse model of fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Age-Dependent Long-Term Potentiation Deficits in the Prefrontal Cortex of the Fmr1 Knockout Mouse Model of Fragile X Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Selective role of the catalytic PI3K subunit p110β in impaired higher order cognition in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Quantitative phosphoproteomics of murine Fmr1-KO cell lines provides new insights into FMRP-dependent signal transduction mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Resilience to audiogenic seizures is associated with p-ERK1/2 dephosphorylation in the subiculum of Fmr1 knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Dysregulation of mTOR signaling in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Analysis of FMR1 deletion in a subpopulation of post-mitotic neurons in mouse cortex and hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

The mGluR theory of fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Correction of fragile X syndrome in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of Fmr1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Open-label memantine in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Neuroendocrine alterations in the fragile X mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Decreased expression of the GABAA receptor in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA(A)-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Open-label riluzole in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Effects of Acamprosate on Neuronal Receptors and Ion Channels Expressed inXenopusOocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Acamprosate: recent findings and future research directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Brief report: acamprosate in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Effect of metadoxine on striatal dopamine levels in C57 black mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Open-label add-on treatment trial of minocycline in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Cholesterol levels in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Involvement of cholinergic and gabaergic systems in the fragile X knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Fragile X syndrome: assessment and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Aripiprazole in autism spectrum disorders and fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Outcome measures for clinical trials in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale-revised for fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0542-Y

Screening for fragile X syndrome: a literature review and modelling study

21 January 2018

1 reference

12 December 2020

Male carriers of the FMR1 premutation show altered hippocampal-prefrontal function during memory encoding

1 reference

12 December 2020

The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.

1 reference

12 December 2020

SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients

1 reference

12 December 2020

Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome.

1 reference

12 December 2020

Prevalence of fragile X syndrome

1 reference

12 December 2020

Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys

1 reference

12 December 2020

Role for Rapid Dendritic Protein Synthesis in Hippocampal mGluR-Dependent Long-Term Depression

1 reference

12 December 2020

A controlled trial of stimulant medication in children with the fragile X syndrome

1 reference

12 December 2020

Autism spectrum disorder in Fragile X syndrome: differential contribution of adaptive socialization and social withdrawal

1 reference

12 December 2020

The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome

1 reference

12 December 2020

Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study

1 reference

12 December 2020

Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor

1 reference

12 December 2020

Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation

1 reference

12 December 2020

Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey.

1 reference

12 December 2020

Gene expression changes in the MAPK pathway in both Fragile X and Down syndrome human neural progenitor cells.

1 reference

12 December 2020

Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial

1 reference

12 December 2020

Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature

1 reference

12 December 2020

The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1

1 reference

12 December 2020

Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model

1 reference

12 December 2020

The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals

1 reference

12 December 2020

Specification of the neurobehavioral phenotype in males with fragile X syndrome.

1 reference

12 December 2020

Induction of long-term depression in cerebellar Purkinje cells requires a rapidly turned over protein

1 reference

12 December 2020

The group I metabotropic glutamate receptor agonist (S)-3,5-dihydroxyphenylglycine induces a novel form of depotentiation in the CA1 region of the hippocampus.

1 reference

12 December 2020